TY - JOUR
T1 - Percutaneous interventional treatment of extracranial vertebral artery stenosis with coronary stents
AU - Ko, Young Guk
AU - Park, Sungha
AU - Kim, Jong Youn
AU - Min, Pil Ki
AU - Choi, Eui Young
AU - Jung, Jae Hun
AU - Joung, Boyoung
AU - Choi, Donghoon
AU - Jang, Yangsoo
AU - Shim, Won Heum
PY - 2004/8/31
Y1 - 2004/8/31
N2 - Stenosis of extracranial vertebral artery (VA) is not an infrequent lesion, and it can pose a significant clinical problem. However, the standard treatment for a significant VA stenosis has still not been established. Here in this study, we report our experiences of VA stenting in 25 patients (age 56.2 ± 15.2 years, male 76%). The patients had comorbidities as follows: DM (36%), hypertension (64%), Takayasu's (12%) and Behcet's diseases (4%). There were combined involvement of other vessels such as the coronary artery (72%), carotid artery (36%), subclavian artery (32%) and the contralateral vertebral artery (24%). Indications for stenting were prior stroke or symptoms related to vertebrobasilar ischemia in 11 patients, and an asymptomatic but angiographically significant stenosis (> 70% stenosis) in 14 patients. Twenty-three balloon-expandable stents and two self-expandable stents were deployed. A drug-eluting coronary stent and distal balloon protection device were each used in one case. A technically successful procedure was achieved in all patients. The baseline reference diameter was 4.7 ± 1.3 mm, minimal luminal diameter (MLD) 1.0 ± 0.6 mm (diameter stenosis 77.8 ± 12.5%) and lesion length 6.4 ± 3.9 mm. After stenting and adjuvant dilation, the MLD was increased to 4.5 ± 0.9 mm (diameter stenosis 3.1 ± 17.9%). There were no procedure-related complications. During the further follow-up period of 25 (3-49) months, no stroke or death occurred. Restenosis was observed in 4 (30.8%) of 13 eligible patients. In conclusion, VA stenting is feasible with a high degree of technical success, and this treatment is associated with a relatively low incidence of procedure-related complications. However, a relative high rate of in-stent restenosis remains as a problem to be resolved.
AB - Stenosis of extracranial vertebral artery (VA) is not an infrequent lesion, and it can pose a significant clinical problem. However, the standard treatment for a significant VA stenosis has still not been established. Here in this study, we report our experiences of VA stenting in 25 patients (age 56.2 ± 15.2 years, male 76%). The patients had comorbidities as follows: DM (36%), hypertension (64%), Takayasu's (12%) and Behcet's diseases (4%). There were combined involvement of other vessels such as the coronary artery (72%), carotid artery (36%), subclavian artery (32%) and the contralateral vertebral artery (24%). Indications for stenting were prior stroke or symptoms related to vertebrobasilar ischemia in 11 patients, and an asymptomatic but angiographically significant stenosis (> 70% stenosis) in 14 patients. Twenty-three balloon-expandable stents and two self-expandable stents were deployed. A drug-eluting coronary stent and distal balloon protection device were each used in one case. A technically successful procedure was achieved in all patients. The baseline reference diameter was 4.7 ± 1.3 mm, minimal luminal diameter (MLD) 1.0 ± 0.6 mm (diameter stenosis 77.8 ± 12.5%) and lesion length 6.4 ± 3.9 mm. After stenting and adjuvant dilation, the MLD was increased to 4.5 ± 0.9 mm (diameter stenosis 3.1 ± 17.9%). There were no procedure-related complications. During the further follow-up period of 25 (3-49) months, no stroke or death occurred. Restenosis was observed in 4 (30.8%) of 13 eligible patients. In conclusion, VA stenting is feasible with a high degree of technical success, and this treatment is associated with a relatively low incidence of procedure-related complications. However, a relative high rate of in-stent restenosis remains as a problem to be resolved.
UR - http://www.scopus.com/inward/record.url?scp=4644330094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644330094&partnerID=8YFLogxK
U2 - 10.3349/ymj.2004.45.4.629
DO - 10.3349/ymj.2004.45.4.629
M3 - Article
C2 - 15344203
AN - SCOPUS:4644330094
SN - 0513-5796
VL - 45
SP - 629
EP - 634
JO - Yonsei Medical Journal
JF - Yonsei Medical Journal
IS - 4
ER -